propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
Published 5 months ago • 47 plays • Length 0:44Download video MP4
Download video MP3
Similar videos
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
5:36
propel trial
-
10:21
profound: olaparib vs enzalutamide or abiraterone for mcrpc with hrr gene alterations
-
1:27
hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
3:47
elucidating hrrm status in patients with mcrpc in the propel trial
-
1:19
highlights in prostate cancer from esmo
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
1:39
challenges in the field of parpi treatment for mcrpc
-
4:30
profound: olaparib for hrr mcrpc
-
5:12
magnitude shows benefit of add-on niraparib for mutated mcrpc | gerhardt attard
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
12:24
gu asco symposium 2022 summary